Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore

Qianhuang Ian Q Wu, MBBS, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, Michelle Poon, MBBS, MRCP, FRCPATH, Lip Kun Tan, MBBS, FRCP, FRCPath, Yang Liang Boo, MD, Yeow Tee Goh, MBBS, Aloysius YL Ho, MBBS,FRCP,FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141581

Published: 2020

Journal Articles

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Colin Phipps, MD, Chandramouli Nagarajan, MBBS, Lawrence Ng, MBBS, Jane L Chua, Yunxin Chen, MBBS, Shin Yeu Ong, MD, Melinda Si Yun Tan, MBBS, Nicholas Francis Grigoropoulos, MD PhD, Sathish Gopalakrishnan, MD, Heng Joo Ng, MBBS, William YK Hwang, MBBS, Yeow Tee Goh, MBBS, Yuh Shan Lee, MBBS

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-142275

Published: 2020

Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Blood (2020) 136 (Supplement 1): 47–50.

https://doi.org/10.1182/blood-2020-139677

Published: 2020

Journal Articles

Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells

Kar Wai Tan, PhD, Zhihui Li, Joey Lai, Dianyan Guo, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, Shang Li, MD PhD, Connie J. Eaves, PhD, Yeow Tee Goh, MBBS, Alice Cheung, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-140667

Published: 2020

Journal Articles

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-135880

Published: 2020

Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD

Blood (2018) 132 (Supplement 1): 792.

https://doi.org/10.1182/blood-2018-99-113609

Published: 2018

Journal Articles

Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas

Yunxin Chen, MBBS, Chandramouli Nagarajan, Nicholas Francis Grigoropoulos, Shin-Yeu Ong, MD, Kit Yan Loh, Allan Zhi Kai Goh, Yeow Tee Goh, MBBS, MD, Yuh Shan Lee, FRCPath, MRCP, MBBS

Blood (2018) 132 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2018-99-112732

Published: 2018

Journal Articles

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Blood (2018) 132 (Supplement 1): 5637.

https://doi.org/10.1182/blood-2018-99-116844

Published: 2018

Journal Articles

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Blood (2018) 132 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2018-99-118364

Published: 2018

Journal Articles

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Dong-Wook Kim, MD PhD, Yeow Tee Goh, MBBS,MD, Iryna Dyagil, MDPhD, Katia B Pagnano, MD, Árpád Bátai, MD, Anna G Turkina, Prof., MD, Jean M. Aguiar, RN, Eric Leip, PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 900.

https://doi.org/10.1182/blood.V130.Suppl_1.900.900

Published: 2017

Journal Articles

Risk Factors Associated with Survival Outcome in Patients with Chronic Myeloid Leukaemia in Accelerated Phase Treated with Tyrosine Kinase Inhibitors

Kee Yon, Lionel See, MD, Kok Chong Bernard Yap, MD, Dong-Wook Kim, MD PhD, Hein Than, MBBS, Yeow-Tee Goh, MBBS, MMed

Blood (2016) 128 (22): 1222.

https://doi.org/10.1182/blood.V128.22.1222.1222

Published: 2016

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

Brian Gabriel Jiang, Dong-Wook Kim, MD, Lee-Yung Shih, MD, Charles Chuah, Hein Than, MD, Ming-Chung Kuo, MD, HuiHua Li, PhD, John Carson Allen, Jr., PhD, Lionel KY See, Bernard KC Yap, Yeow-Tee Goh, MBBS, MMed

Blood (2015) 126 (23): 4044.

https://doi.org/10.1182/blood.V126.23.4044.4044

Published: 2015

Journal Articles

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Oliver G. Ottmann, MD, Giuliana Alimena, Daniel J. DeAngelo, MD PhD, Yeow-Tee Goh, MBBS, MMed, Michael C. Heinrich, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francois-Xavier Mahon, MD PhD Professor, Michael J. Mauro, MD, Hironobu Minami, MD D.MDSci., Marie Huong Nguyen, MD, Delphine Rea, Juan Luis Steegmann, MD, Arkendu Chatterjee, Varsha Iyer, Noelia Martinez, Gary J. Vanasse, MD, Kim Dong-Wook, MD PhD

Blood (2015) 126 (23): 138.

https://doi.org/10.1182/blood.V126.23.138.138

Published: 2015

Journal Articles

Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma

Marc S Raab, MD PhD, Enrique M Ocio, Sheeba K. Thomas, MD, Andreas Günther, MD, Yeow-Tee Goh, MBBS,MMed, Daniel Lebovic, MD, Andrzej Jakubowiak, MD PhD, Dongweon Song, F Xiang, Apurva Patel, K. Gary Vanasse, MD, Shaji Kumar, MD

Blood (2014) 124 (21): 301.

https://doi.org/10.1182/blood.V124.21.301.301

Published: 2014

Journal Articles

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Yeow-Tee Goh, MBBS,MMed, William YK Hwang, FRCP, FAMS, MMed, MRCP, MBBS, Colin Phipps Diong, Yap chun Hsien, bsc, Kevin Tay, MD, Soon Thye Lim, MBBS, MRCP, Yuh Shan Lee, MBBS, MRCP, Soo Chin Ng, MD, S Fadilah, MBBS, Won Seog Kim, Daryl Tan, MD

Blood (2014) 124 (21): 503.

https://doi.org/10.1182/blood.V124.21.503.503

Published: 2014

Journal Articles

Essential Thrombocythaemia in Young Adults: Clinical Characteristics and Outcomes – a Single Center Experience

Grace Kam, MBBS, MRCP, Richard Yiu, Ai Leen Ang, MBBS, MMed, (Internal, Medicine), Yvonne SM Loh, MBBS, MRCP, Yeh Ching Linn, MBBS, Lai Heng Lee, MBBS, MMed, Yeow Tee Goh, MBBS, MMed, Gee Chuan Wong, MBBS, MRCP, FRCP

Blood (2012) 120 (21): 5060.

https://doi.org/10.1182/blood.V120.21.5060.5060

Published: 2012

Journal Articles

A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia

Axel M Hillmer, PhD, King-Pan Ng, PhD, Charles Chuah, MBChB, FRCPE, MD, Wen Chun Juan, B.Sc, Tun-Kiat Ko, PhD, Audrey S.M. Teo, M.Sc, Pramila N Ariyaratne, M.Sc, Naoto Takahashi, MD, PhD, Kenichi Sawada, MD, PhD, Yao Fei, M.Sc, Wah Heng Lee, PhD, Weijie Huang, B.Sc, John C Allen, Jr., PhD, Xing Yi Woo, PhD, Niranjan Nagarajan, PhD, Vikrant Kumar, PhD, Anbupalam Thalamuthu, PhD, Wan Ting Poh, B.S, Ai Leen Ang, MBBS, MMed, (Internal, Medicine), Hae Tha Mya, M.B.B.S, Gee Fung How, PhD, Li Yi Yang, B.Sc, Liang Piu Koh, M.B.B.S, Veera S Nadarajan, M.B.B.S, Wee-Joo Chng, M.B.Ch.B, Hein Than, M.B.B.S, Lay Cheng Lim, MD, Yeow-Tee Goh, MBBS, MMed, Markus M Nöthen, M.D, Tien Y Wong, M.D, PhD, Atif Shahab, PhD, Xiaoan Ruan, PhD, Valère Cacheux-Rataboul, PhD, Wing-Kin Sung, PhD, Yijun Ruan, PhD, S. Tiong Ong, M.A., M.B.B.Ch., M.R.C.P., (UK)

Blood (2011) 118 (21): 1666.

https://doi.org/10.1182/blood.V118.21.1666.1666

Published: 2011

Journal Articles

Evaluation of Human Polyomavirus (BKV)–Specific T Cell Immune Reconstitution in Allogeneic Haematopoietic Stem Cell Transplant Recipients,

Francesca Lorraine Wei Inng Lim, MBBS, MRCP, MMED, Ai Ling Teo, BSc, Yvonne SM Loh, MBBS, MRCP, William YK Hwang, MBBS, FRCP, FAMS, Yeow-Tee Goh, MBBS, MMed, Khoon Lin Ling, MBBS, MRCP, Yeh Ching Linn, MD

Blood (2011) 118 (21): 3223.

https://doi.org/10.1182/blood.V118.21.3223.3223

Published: 2011

NARROW

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Risk Factors Associated with Survival Outcome in Patients with Chronic Myeloid Leukaemia in Accelerated Phase Treated with Tyrosine Kinase Inhibitors

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Essential Thrombocythaemia in Young Adults: Clinical Characteristics and Outcomes – a Single Center Experience

A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia

Evaluation of Human Polyomavirus (BKV)–Specific T Cell Immune Reconstitution in Allogeneic Haematopoietic Stem Cell Transplant Recipients,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only